Lineage Cell Therapeutics Inc (XTAE:LCTX)
₪ 3.294 0.074 (2.3%) Market Cap: 632.94 Mil Enterprise Value: 497.81 Mil PE Ratio: 0 PB Ratio: 2.44 GF Score: 62/100

Q2 2024 Lineage Cell Therapeutics Inc Earnings Call Transcript

Aug 08, 2024 / 08:30PM GMT
Release Date Price: ₪3.3 (-2.97%)

Key Points

Positve
  • Lineage Cell Therapeutics Inc (LCTX) has successfully expanded its alliance with Roche and Genentech, reflecting positive developments in their OpRegen program.
  • The company has opened its first ex-US clinical site for the OpRegen Phase 2 trial in Israel, enhancing the program's global reach.
  • Lineage Cell Therapeutics Inc (LCTX) has a strong cash position with $38.5 million in cash, cash equivalents, and marketable securities, expected to support operations into Q4 2025.
  • The company is making strategic investments in its pipeline, including promising preclinical programs like ANP1 for hearing loss and a new undisclosed neurology program.
  • Lineage Cell Therapeutics Inc (LCTX) maintains a disciplined approach to fiscal management, allowing it to navigate the challenging biotech market environment effectively.
Negative
  • The biotech sector remains in a prolonged bear market, affecting investor sentiment and capital availability for Lineage Cell Therapeutics Inc (LCTX).
  • The company experienced a decrease in total revenues to $1.4 million, down from $3.2 million in the same period in 2023, primarily due to lower collaboration and licensing revenues.
  • Lineage Cell Therapeutics Inc (LCTX) is facing delays in FDA review for its IND amendment related to the OPC1 program, impacting the timeline for initiating the DOSED study.
  • The company reported a net loss of $5.8 million for the quarter, an increase from the $5.2 million loss in the same period in 2023.
  • There is uncertainty regarding the timing and availability of clinical data from the OpRegen trial, as Lineage does not control the release of this information.
Operator

Welcome to the Lineage Cell Therapeutics second quarter 2024 conference call. At this time, all participants are in a listen only mode. An audio webcast of this call is available on the Investors section of Lineage website at www.lineagecell.com.

This call is subject to copyright. It is the property of Lineage and recordings, reproduction or transmission of this call without the express written consent of Lineage, are strictly prohibited. As a reminder, today's call is being recorded. I would now like to introduce your host for today's call Ms. Ioana Hone, Head of Investor Relations at Lineage. Ms. Hone, please go ahead.

Ioana Hone
Lineage Cell Therapeutics Inc - Head of Investor Relations

Thank you. Good afternoon and thank you for joining us. a press release reporting our second quarter 2024 financial results was issued earlier today August 8, 2024, and can be found on the Investors section of our website.

Please note that today's remarks and responses to your questions

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot